<?xml version='1.0' encoding='utf-8'?>
<document id="17024799"><sentence text="Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients."><entity charOffset="0-9" id="DDI-PubMed.17024799.s1.e0" text="Tamoxifen" /></sentence><sentence text="Tamoxifen has been reported to potentiate the anticoagulant effect of warfarin and also to increase the plasma level of phenytoin, which are mainly metabolized by CYP2C9"><entity charOffset="0-9" id="DDI-PubMed.17024799.s2.e0" text="Tamoxifen" /><entity charOffset="120-129" id="DDI-PubMed.17024799.s2.e1" text="phenytoin" /><pair ddi="false" e1="DDI-PubMed.17024799.s2.e0" e2="DDI-PubMed.17024799.s2.e0" /><pair ddi="false" e1="DDI-PubMed.17024799.s2.e0" e2="DDI-PubMed.17024799.s2.e1" /></sentence><sentence text=" The aim of this study was to determine the influence of tamoxifen on CYP2C9 activity in vivo in humans"><entity charOffset="57-66" id="DDI-PubMed.17024799.s3.e0" text="tamoxifen" /></sentence><sentence text=" Thirteen breast cancer patients who would start tamoxifen following cytotoxic chemotherapy were enrolled in the study"><entity charOffset="49-58" id="DDI-PubMed.17024799.s4.e0" text="tamoxifen" /></sentence><sentence text=" A single oral dose of 25 mg losartan was given to the patients 2 days before and 2 weeks after starting tamoxifen therapy"><entity charOffset="29-37" id="DDI-PubMed.17024799.s5.e0" text="losartan" /><entity charOffset="105-114" id="DDI-PubMed.17024799.s5.e1" text="tamoxifen" /><pair ddi="false" e1="DDI-PubMed.17024799.s5.e0" e2="DDI-PubMed.17024799.s5.e0" /><pair ddi="false" e1="DDI-PubMed.17024799.s5.e0" e2="DDI-PubMed.17024799.s5.e1" /></sentence><sentence text=" Losartan and E3174 in 8-hour urine samples were measured by HPLC"><entity charOffset="1-9" id="DDI-PubMed.17024799.s6.e0" text="Losartan" /><entity charOffset="14-19" id="DDI-PubMed.17024799.s6.e1" text="E3174" /><pair ddi="false" e1="DDI-PubMed.17024799.s6.e0" e2="DDI-PubMed.17024799.s6.e0" /><pair ddi="false" e1="DDI-PubMed.17024799.s6.e0" e2="DDI-PubMed.17024799.s6.e1" /></sentence><sentence text=" Tamoxifen significantly increased the average urinary losartan/E3174 ratio from 0"><entity charOffset="1-10" id="DDI-PubMed.17024799.s7.e0" text="Tamoxifen" /><entity charOffset="55-63" id="DDI-PubMed.17024799.s7.e1" text="losartan" /><entity charOffset="64-71" id="DDI-PubMed.17024799.s7.e2" text="E3174" /><pair ddi="false" e1="DDI-PubMed.17024799.s7.e0" e2="DDI-PubMed.17024799.s7.e0" /><pair ddi="false" e1="DDI-PubMed.17024799.s7.e0" e2="DDI-PubMed.17024799.s7.e1" /><pair ddi="false" e1="DDI-PubMed.17024799.s7.e0" e2="DDI-PubMed.17024799.s7.e2" /><pair ddi="false" e1="DDI-PubMed.17024799.s7.e1" e2="DDI-PubMed.17024799.s7.e1" /><pair ddi="false" e1="DDI-PubMed.17024799.s7.e1" e2="DDI-PubMed.17024799.s7.e2" /></sentence><sentence text="73 (CI 95% = 0" /><sentence text="15 - 2" /><sentence text="30) to 1" /><sentence text="66 (CI 95% = 0" /><sentence text="68 - 5" /><sentence text="20), after 2 weeks of treatment (p = 0" /><sentence text="002)" /><sentence text=" Tamoxifen inhibited CYP2C9 activity in breast cancer patients within two weeks of its administration"><entity charOffset="1-10" id="DDI-PubMed.17024799.s15.e0" text="Tamoxifen" /></sentence><sentence text=" The inhibition of CYP2C9 activity may be a possible explanation for the drug-drug interaction of tamoxifen with CYP2C9 substrates"><entity charOffset="98-107" id="DDI-PubMed.17024799.s16.e0" text="tamoxifen" /></sentence><sentence text="" /></document>